Lakeside Biological released its unaudited financial performance for the first half of the 2025 fiscal year and updated the financial guidance for the entire year.

In the first half of the 2025 fiscal year, revenue reached 0.3719 billion yuan, a year-on-year increase of 36.2%. The gross profit for the first half of the 2025 fiscal year was 0.3073 billion yuan, an increase of 39.1% year-on-year; the gross margin increased from 80.9% in the same period last year to 82.6%. Total operating expenses in the first half of the 2025 fiscal year decreased by 31.6%, totaling 0.2764 billion yuan. The net income for the first half of the 2025 fiscal year was 20.58 million yuan, while the net income under non-GAAP was 30.45 million yuan; in the same period of 2024, the recorded figures were (under GAAP and non-GAAP.

PR NewswireDec 20 11:05

LakeShore Biopharma Sees FY25 Revenues To Be Between RMB 665 Million - RMB 700 Million, Indicating Growth Of 16%-22% YoY

BenzingaDec 19 22:24

LakeShore Biopharma H1 2025 EPS $0.02; Revenue $53.08M

BenzingaDec 19 22:23

Press Release: LakeShore Biopharma Reports Unaudited Financial Results for the First Half of Fiscal Year 2025 and Updates Full-Year Guidance

Dow JonesDec 19 22:05

12 Health Care Stocks Moving In Monday's Pre-Market Session

BenzingaDec 17 05:05

Reported Earlier, LakeShore Biopharma Takes Decisive Action In Response To Criminal Allegations Against Former Chairman, Yi Zhang

BenzingaDec 13 15:14